By clicking Continue, you confirm that you are a healthcare professional In the UK.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
If you get any side effects, talk to your healthcare professional. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Sanofi and Regeneron are collaborating in a global development programme and commercialisation for Dupixent.
DUPIXENT Summary of Product Characteristics. September 2021.
Sanofi Data on File. MAT-IE-2000837 (v3.0).
Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
Sears AV, et al. Br J Dermatol. 2020. doi: 10.1111/bjd.19631. Online ahead of print.
Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Poster P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
Gandhi NA, et al. Nature Rev Drug Disc. 2016; 15: 35–50.